Literature DB >> 17029134

Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy.

T Santantonio1, E Medda, C Ferrari, P Fabris, G Cariti, M Massari, S Babudieri, M Toti, R Francavilla, F Ancarani, G Antonucci, G Scotto, V Di Marco, G Pastore, T Stroffolini.   

Abstract

BACKGROUND: The epidemiology of acute hepatitis C has changed during the past decade in Western countries. Acute HCV infection has a high rate of chronicity, but it is unclear when patients with acute infection should be treated.
METHODS: To evaluate current sources of hepatitis C virus (HCV) transmission in Italy and to assess the rate of and factors associated with chronic infection, we enrolled 214 consecutive patients with newly acquired hepatitis C during 1999-2004. The patients were from 12 health care centers throughout the country, and they were followed up for a mean (+/- SD) period of 14+/-15.8 months. Biochemical liver tests were performed, and HCV RNA levels were monitored.
RESULTS: A total of 146 patients (68%) had symptomatic disease. The most common risk factors for acquiring hepatitis C that were reported were intravenous drug use and medical procedures. The proportion of subjects with spontaneous resolution of infection was 36%. The average timespan from disease onset to HCV RNA clearance was 71 days (range, 27-173 days). In fact, 58 (80%) of 73 patients with self-limiting hepatitis experienced HCV RNA clearance within 3 months of disease onset. Multiple logistic regression analyses showed that none of the variables considered (including asymptomatic disease) were associated with increased risk of developing chronic hepatitis C.
CONCLUSIONS: These findings underscore the importance of medical procedures as risk factors in the current spread of HCV infection in Italy. Because nearly all patients with acute, self-limiting hepatitis C--both symptomatic and asymptomatic--have spontaneous viral clearance within 3 months of disease onset, it seems reasonable to start treatment after this time period ends to avoid costly and useless treatment.

Entities:  

Mesh:

Year:  2006        PMID: 17029134     DOI: 10.1086/507640

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  35 in total

1.  The seroprevalence of hepatitis C virus (HCV) among 559,890 first-time volunteer blood donors in China reflects regional heterogeneity in HCV prevalence and changes in blood donor recruitment models.

Authors:  Yongshui Fu; Wenjie Xia; Yizhong Wang; Linwei Tian; Oliver G Pybus; Ling Lu; Kenrad Nelson
Journal:  Transfusion       Date:  2010-04-23       Impact factor: 3.157

Review 2.  Acute hepatitis C virus infection: a chronic problem.

Authors:  Jason T Blackard; M Tarek Shata; Norah J Shire; Kenneth E Sherman
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

Review 3.  Acute hepatitis C: clinical and laboratory diagnosis, course of the disease, treatment.

Authors:  E Sagnelli; T Santantonio; N Coppola; M Fasano; M Pisaturo; C Sagnelli
Journal:  Infection       Date:  2014-03-12       Impact factor: 3.553

4.  Acute hepatitis C virus infection in a nurse trainee following a needlestick injury.

Authors:  Renzo Scaggiante; Liliana Chemello; Roberto Rinaldi; Giovanni Battista Bartolucci; Andrea Trevisan
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

Review 5.  Role of occult hepatitis B virus infection in chronic hepatitis C.

Authors:  Nicola Coppola; Lorenzo Onorato; Mariantonietta Pisaturo; Margherita Macera; Caterina Sagnelli; Salvatore Martini; Evangelista Sagnelli
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

Review 6.  Acute hepatitis C in an HIV-infected patient: a case report and review of literature.

Authors:  Todd H Driver; Norah Terrault; Varun Saxena
Journal:  J Gen Intern Med       Date:  2012-11-14       Impact factor: 5.128

7.  Acute hepatitis C: prospects and challenges.

Authors:  Sanaa M Kamal
Journal:  World J Gastroenterol       Date:  2007-12-28       Impact factor: 5.742

8.  Immune complexed (IC) hepatitis C virus (HCV) in chronically and acutely HCV-infected patients.

Authors:  E Riva; F Maggi; F Abbruzzese; F Bellomi; G Giannelli; A Picardi; C Scagnolari; A Folgori; E Spada; E Piccolella; F Dianzani; G Antonelli
Journal:  Med Microbiol Immunol       Date:  2008-08-12       Impact factor: 3.402

9.  Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection.

Authors:  Kimberly Page; Judith A Hahn; Jennifer Evans; Stephen Shiboski; Paula Lum; Eric Delwart; Leslie Tobler; William Andrews; Lia Avanesyan; Stewart Cooper; Michael P Busch
Journal:  J Infect Dis       Date:  2009-10-15       Impact factor: 5.226

10.  Symptomatic acute hepatitis C in Egypt: diagnosis, spontaneous viral clearance, and delayed treatment with 12 weeks of pegylated interferon alfa-2a.

Authors:  Noha Sharaf Eldin; Soheir Ismail; Hala Mansour; Claire Rekacewicz; Moustafa El-Houssinie; Sherif El-Kafrawy; Saeed El Aidi; Mohamed Abdel-Hamid; Gamal Esmat; Stanislas Pol; Arnaud Fontanet; Mostafa K Mohamed
Journal:  PLoS One       Date:  2008-12-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.